Search results
18 wrz 2021 · In this review, we focused our attention on data obtained from human studies analyzing, at each level of disease prevention (i.e., primary, secondary, tertiary and quaternary), the positive impact of PA /exercise in ER+ BC, a subtype representing approximately 70% of all BC diagnoses.
25 sie 2016 · The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought to provide prospective evidence of the...
9 sty 2024 · In addition, cancer antigen 15-3 (CA 15-3) and cancer antigen 27.29 (CA 27.29) are sometimes used to monitor response to breast cancer treatment. Cancer antigen 125 (CA 125) is the most widely used biomarker to monitor response to treatment in women diagnosed with ovarian cancer.
Almost all women with estrogen receptor (ER)–positive primary breast cancer are offered adjuvant endocrine therapy, and a highly relevant clinical question is who remains at high risk for distant recurrence despite completion of primary adjuvant therapy.
1 gru 2021 · In a prospective trial, we randomly assigned women with hormone-receptor–positive, HER2-negative breast cancer, one to three positive axillary lymph nodes, and a recurrence score of 25 or...
20 lut 2019 · Breast cancer is the most common cause of female cancer deaths in the western world, with early detection of cancer being pivotal for an improved prognosis and survival. Mammography is the mainstay of breast cancer screening and diagnosis [1–3].
Age is one of the most important risk factors for the development of breast cancer. Nearly a third of all breast cancer cases occur in older women (aged ≥70 years), with most cases being oestrogen receptor-positive (ER+).
